Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

Share this content:
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.

Targeted therapy with dabrafenib is active and well-tolerated among patients with relapsed or refractory BRAF V600 mutation-positive pediatric low-grade glioma, according to a study presented at the European Society for Medical Oncology (ESMO) 2016 Congress.1

Approximately 15% to 20% of children with low-grade glioma harbor BRAF V600 mutations, and these patients have historically worse survival and lower objective response rates to first- and second-line chemotherapy relative to patients with BRAF V600 wild-type disease. Researchers evaluated the activity of targeted BRAF inhibition with dabrafenib among pediatric patients with recurrent or progressive disease.

For the open-label, phase 1/2a study (ClinicalTrials.gov Identifier: NCT01677741), investigators enrolled 32 patients aged 2 to 17 years with BRAF V600-mutant relapsed or refractory low-grade glioma. Overall, 24 patients received the recommended phase 2 dose of second-line dabrafenib.

The overall response rate was 41% (95% CI, 24-59) per independent review, which included 2 complete responses and 11 partial responses. Median duration of response was 11 months and 8 responses were ongoing at the time of analysis.

Thirteen additional patients had stable disease for 6 months longer.

RELATED: The Next Frontier: Radiotherapy Plus Immunotherapy for Melanoma Brain Metastases

The confirmed overall response rate per investigator assessment was 72% (95% CI, 53-86), which included 1 complete response and 2 partial responses.

No new safety signals were observed and there were no reports of cutaneous squamous cell carcinoma. The most common adverse events were low-grade pyrexia, vomiting, fatigue, headache, and rash. Three patients experienced grade 3 to 4 pneumonia.                              

Reference

  1. Kieran MW, Bouffet E, Tabori U, et al. The first study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas. Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs